Professor David Allsup's Recognition (58)

Member of Trial Managment Group for STATIC clinical trial
2022 - 2030

Affiliated Organisations	Hull York Medical School
Projects	STATIC: A Randomised Phase III Trial Comparing Continuous with Intermittent Treatment Strategies in Chronic Lymphocytic Leukaemia (CLL)

Member of United Kingdom Haemophilia Directors Executive Commitee
2021 - 2025

Affiliated Organisations	Hull York Medical School

Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL: Results of the Phase III NCRI FLAIR Trial
2021 - 2021

Description	Presentation at American Society of Haematology
Affiliated Organisations	Hull York Medical School

B-MORE, Baseline Analysis from a 24-month Prospective, Non-interventional, Multicentre Study on Real-world Effectiveness and Usage of Recombinant Factor IX Fc (rFIXFc) in Haemophilia B
2021 - 2021

Description	Poster presentation at International Society for Thrombosis and Haemostasis
Affiliated Organisations	Hull York Medical School

Ten-year follow-up of 415 CLL patients treated with fludarabine cyclophosphamide-based chemoimmunotherapy in the frontline ARCTIC and ADMIRE trials, a comprehensive assessment of prognostic factors.
2021 - 2021

Description	Poster presentation at European Haematology Association
Affiliated Organisations	Hull York Medical School

The impact of bacterial superantigens on T cell exhaustion in chronic lymphocytic leukemia (CLL) patients
2021 - 2021

Description	Poster presentation at British Society for Immunology
Affiliated Organisations	Hull York Medical School

Member of trial management group for BioDrive
2021 - 2026

Description	Cheif investigator and member of trial management group for BioDrive trial
Projects	The Biomarker Driven Antifungal Stewardship in AML: The BioDriveAFS Trial

Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial
2021 - 2021

Description	Presentation at American Society of Haematology
Affiliated Organisations	Hull York Medical School

A single centre study to assess delivery of vaccination advice to patients with chronic lymphocytic leukaemia
2021 - 2021

Description	British Society of Haematology Meeting, virtual
Affiliated Organisations	Hull York Medical School

Btk inhibitors Ibrutinib and Acalabrutinib impair FcγRIIA-mediated responses of healthy donor platelets and Chronic Lymphocytic Leukaemia platelets to bacteria.
2020 - 2020

Description	Co-author on above poster presentation at BSH 2020.
Affiliated Organisations	Hull York Medical School
Org Units	Hull York Medical School

Splenectomy in immune thrombocytopenia: do changing treatment patterns for ITP affect outcome? Data from the UK ITP registry
2020 - 2020

Description	Co-author on above presentation at BSH 2020
Affiliated Organisations	Hull York Medical School

Btk Inhibitor Ibrutinib Impairs FcγRIIa-Mediated Responses of Platelets from Healthy Donors and Chronic Lymphocytic Leukaemia Patients to Bacteria
2020 - 2020

Description	Authors: Leigh Naylor-Adamson1, Zoe Booth1, Simon P. Hart3, David J Allsup1,4, and Mònica Arman1 Affiliations: 1Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, University of Hull; 2Respiratory Research Group, Hull York Medical School, University of Hull; 3Department of Haematology, Queens Centre for Oncology and Haematology, Castle Hill Hospital, Hull and East Yorkshire Hospitals NHS Trust. Poster British Society Haematology Meeting 2020
Affiliated Organisations	Hull York Medical School
Projects	CLL Research
Org Units	Hull York Medical School

Telomere Length and CD49d Cooperate with IGHV Gene Status As Predictors of Long-Term Progression-Free Survival in CLL Patients Treated with FCR-Based Regimens
2020 - 2020

Description	Poster presentation American Society for Haematology Andrea GS Pepper, PhD1*, Antonella Zucchetto, PhD2*, Kevin Norris, PhD3*, Erika Tissino, PhD4*, Jerry Polesel5*, Zarni Soe6*, David Allsup7*, Anna Hockaday8*, Pei Loo Ow9*, Peter Hillmen, MBChB, PhD10*, Andrew Rawstron, PhD11*, Daniel Catovsky, MD, FRCP12, Riccardo Bomben, PhD2*, Duncan M Baird, PhD13*, Christopher Fegan14*, Valter Gattei, MD15 and Chris Pepper, BSc, PhD16
Affiliated Organisations	Hull York Medical School
Projects	STATIC: A Randomised Phase III Trial Comparing Continuous with Intermittent Treatment Strategies in Chronic Lymphocytic Leukaemia (CLL) CLL Research
Org Units	Hull York Medical School

Bruton's Tyrosine Kinase Inhibitors Impair Fcγriia-Mediated Responses of Healthy Donor Platelets and Chronic Lymphocytic Leukaemia Derived Platelets to Bacteria
2020 - 2020

Description	1748 Bruton's Tyrosine Kinase Inhibitors Impair Fcγriia-Mediated Responses of Healthy Donor Platelets and Chronic Lymphocytic Leukaemia Derived Platelets to Bacteria Program: Oral and Poster Abstracts Session: 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Poster II Hematology Disease Topics & Pathways: Leukemia, Diseases, CLL, Therapies, Biological Processes, Lymphoid Malignancies, Clinically relevant, immune mechanism, pathways Sunday, December 6, 2020, 7:00 AM-3:30 PM Leigh Naylor-Adamson1*, Zoe Booth2*, Simon Hart3*, Russell Patmore4, Sujoy Khan5*, David Allsup6* and Monica Arman6* 1Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, Owston Ferry, ENG, United Kingdom 2Centre for Atherothrombosis and Metabolic Disease, University of Hull, Hull, ENG, United Kingdom 3Respiratory Research Group, Hull York Medical School, Hull, ENG, United Kingdom 4Department of Haematology, Hull and East Yorkshire Hospitals NHS Trust, Hull, ENG, United Kingdom 5Department of Immunology & Allergy, Hull and East Yorkshire Hospitals NHS Trust, Hull, ENG, United Kingdom 6Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, Hull, ENG, United Kingdom
Affiliated Organisations	Hull York Medical School
Projects	CLL Research
Org Units	Hull York Medical School

SPLENECTOMY IN IMMUNE THROMBOCYTOPENIA: DO CHANGING TREATMENT PATTERNS FOR ITP AFFECT OUTCOMES? DATA FROM THE UK ITP REGISTRY
2019 - 2019

Description	European Haematology Association Annual Congress
Affiliated Organisations	Hull York Medical School

Multicenter Genome Wide Association Study Identifies Constitutional Risk Alleles for Progressive Chronic Lymphocytic Leukemia
2019 - 2019

Description

David Allsup, Wei-Yu Lin, Sarah Fordham, Nicola Sunter, Claire Elstob, Thahira Rahman, Elaine Willmore, Colin Shepherd, Gordon Strathdee, Timothy Barrow, Tryfonia Mainou-Fowler, Rachel Piddock, Helen Marr, Jonathan Wallis, Scott Marshall, Andrew Pettitt, Christopher Pepper, Christopher Fegan, Francesco Forconi, Martin JS Dyer, Sandrine Jayne, April Sellors, Anna Schuh, Pauline Robbe David Oscier, Richard S. Houlston, James Bailey, Syed Rais, Alison Bentley, Lynn Cawkwell, Peter Hillmen, Guy Pratt , James Allan. Conference presentation, American Society for Haematology, Orlando, December 2019.

Affiliated Organisations

Hull York Medical School

Fellow Higher Education Academy
2019 - 2025

Affiliated Organisations	Higher Education Academy

Honorary Consultant
2018 - 2025

Description	Honorary Consultant
Affiliated Organisations	Hull University Teaching Hospitals NHS Trust
Projects	STATIC: A Randomised Phase III Trial Comparing Continuous with Intermittent Treatment Strategies in Chronic Lymphocytic Leukaemia (CLL)

Member of Trial Management Group for LIPS
2018 - 2022

Description	Co-investigator, and member of trial management group, of a registry study of acute leukaemia and pregnancy.
Affiliated Organisations	Hull York Medical School
Projects	LIPS: A prospective registry-based cohort study to monitor the diagnosis and management of acute leukaemia in pregnancy

Peer reviewer
2018 - 2023

Description	Peer reviewer for multiple journals including American Journal of Haematology, British Journal of Haematology, Cellular Signalling, Expert Opinion Therapeutic Targets, Leukemia, Leukaemia Research, European Journal of Haematology.